Company
Every investor coverage indicates participated in a round Fibrotech raised.
The transaction that ended Fibrotech's run as a startup, per published coverage. It closes the funding history too, where it is the ladder's last rung.
| Bought by | Kind | Announced | Price | Sources |
|---|---|---|---|---|
| Shire | Acquisition | 2014 | - | Brandon BioCatalyst, Brandon Capital |
Companies Fibrotech acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming Fibrotech. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Melbourne biotech Certa Therapeutics has acquired OccuRx, combining two GPR68 fibrosis pipelines founded by Professor Darren Kelly, and says it will seek Series B funding to advance clinical development.
GBS Ventures reports Novartis has agreed to acquire chronic-pain drug developer Spinifex Pharmaceuticals for US$200 million upfront plus milestones, recalling the company's 2005, 2008 and 2014 venture rounds and its Australian investors.
Also GBS Ventures·novartis.com·clinicalleader.com·Startup Daily·Startup Daily·anthillonline.com·@AuManufacturing·materresearch.org.au·Business News Australia